Dr Nancy Lin (Dana-Farber Cancer Institute, Boston, MA, USA) discusses the updated results of the phase II HER2CLIMB study, which assessed tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated HER2-positive metastatic breast cancer with brain metastases. These results were presented at the San Antonio Breast Cancer Symposium 2021.
Questions
1. What options are currently available to patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer and brain metastases who have disease progression after therapy with multiple HER2-targeted agents? 00:10-01:00
2. Could you give us a brief overview of the HER2CLIMB study and its unique features? 01:00-01:55
3. What were the efficacy and safety findings of the initial analysis of patients with brain metastases at baseline? 01:55-02:30
4. What have the updated findings taught us, and how will they inform clinical practice? 02:30-04:08
5. What questions remain unanswered about the combination of tucatinib, trastuzumab and capecitabine, and what further studies are planned? 04:08-05:22
Speaker Disclosure: Nancy Lin discloses study steering committee at AstraZeneca and research funding (to institution) from SeaGen, Pfizer and Genentech.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the San Antonio Breast Cancer Symposium 2021
